Supplements and Nutraceutical Import Origins 2026: Where Your COGS Actually Lives

If you run a supplement brand, the country printed on your label is almost never the country your gross margin actually depends on. The bottle may say it was made in the US or filled in Canada. The vitamin C, the magnesium, the amino acids, and half the excipients inside it very likely started in China.

That gap between where finished goods ship from and where ingredients originate is the single most misread risk in nutraceutical COGS. Below is what the 2025 US trade data says about both layers, and what it means for a brand trying to protect margin into 2026.

The finished-goods picture looks diversified

Start with the line most brands and brokers actually watch. Supplement-style products that are not in finished dosage form usually clear under HS 2106.90, "food preparations not elsewhere specified," which captures protein blends, gummies, functional powders, and most non-pill formats. In 2025, US imports for consumption on that line totaled $6.04B.

The origins look reassuringly spread out:

China is only 6.4% of that line. Singapore and Canada dominate, with Europe well represented. If this were the whole story, a supplement founder would conclude their China exposure is modest and move on. That conclusion would be wrong, because the finished line is not where the dependence lives.

The ingredient picture is concentrated in two countries

Now look upstream at HS 2936, vitamins and provitamins, the active inputs in most multivitamin, sports, and functional formulas. This is the line that drives your formula cost. Total 2025 US imports were $1.37B, and the concentration is dramatic.

China alone is 56.3% of US vitamin imports. India adds another 6.9%. Together, two countries supply roughly 63% of the active vitamin inputs entering the US. Switzerland (12.6%) and a handful of European producers carry the rest, mostly higher-cost specialty actives.

This is the number that belongs in your risk register, not the 6.4% on the finished line. The same pattern repeats across amino acids, many botanical extracts, and common excipients: China is the low-cost volume producer, India is the second source, and everyone else is a premium fallback.

Why the two layers disagree

Customs records the country of the last substantial transformation, not the origin of every input. A vitamin synthesized in China can be shipped to a blender in Canada, the US, or Singapore, turned into a finished gummy or powder, and then imported into the US as a Canadian or Singaporean product. The finished SKU shows the blender's country. The Chinese active is invisible on that line.

That is why Singapore shows up as 36% of finished food-prep imports while contributing almost nothing to raw vitamin supply: it is a transshipment and contract-manufacturing hub, not an ingredient source. The same dynamic inflates Canada and Ireland on the medicament line (HS 3004, finished dosage forms, a $97.5B line dominated by Ireland at 17%, Switzerland at 16%, and India at 15%). Finished-dosage origins are about tax and manufacturing geography. Ingredient origins are about chemistry, and chemistry says China.

What this does to your COGS

Concentration is only a problem if it touches your cost or your continuity, and here it touches both. The effective duty stack on a China-origin supplement SKU runs about 43% of FOB in 2026, per the Eightx landed cost build by vertical. On a $2.50 FOB 60-count bottle, that is roughly $1.08 in duty, turning the landed cost into about $4.05. Duty is more than two times your logistics cost on supplements, because Section 301 List 3 hits at 25% rather than the 7.5% that lighter categories enjoy.

Supplements also sit in the 35 to 45% effective tariff band overall, per the Eightx tariff impact by COGS analysis, well above beauty at 18 to 25%. And the biggest near-term variable is timing: the Section 122 global 10% tariff is scheduled to sunset on 2026-07-24. If it lapses, your China-origin landed cost drops meaningfully. If it is extended, it does not. You should be modeling both, not one.

For more on how origin mix maps to category-level duty exposure across DTC, see the Eightx import origins hub, the largest US import categories for DTC, and the parallel beauty import origins breakdown. Supplements are a useful contrast case: the finished line looks safe, the ingredient line does not. If you want the financial operating-system view for this specific category, the fractional CFO playbook for supplements brands ties origin risk to cash, margin, and pricing.

What to do about it

Here is the order I would work it if this were a client:

1. Rebuild your bill of materials by country of origin, not country of shipment. For your top ten SKUs, trace each active and major excipient to where it is actually made. Expect China to show up far more than your import paperwork suggests.
2. Rank your ingredients by annual spend and tag single-country exposure. The actives that are both high-spend and single-sourced from one country are your real risk. That is usually three to five inputs, not your whole formula.
3. Qualify a second supplier in a different country for those top inputs. It costs money and time to validate, so do it for the few that matter, not everything. India is the most common second source for China-made actives.
4. Model landed cost in two scenarios for the Section 122 sunset. One with the 10% global tariff extended past 2026-07-24, one without. The delta tells you how much margin is riding on a policy decision you do not control.
5. Hold extra safety stock only on the single-sourced, long-lead actives. Do not blanket-buy inventory and tie up cash. Public supplement brands already run lean: BellRing carries roughly 78 days of inventory, per the Eightx CPG lead-time benchmarks, so target the few inputs where a disruption would actually stop you from shipping rather than padding the whole formula.
6. Reprice deliberately, not reactively. If your duty stack is 43% of FOB and you have not touched price, you are funding the tariff out of your own margin. Build the pass-through into your next pricing cycle.

Methodology

Import figures are US Census Bureau imports for consumption (CON_VAL_YR), full-year 2025, pulled by HS code and partner country at the December cumulative-year reading. Shares are each country divided by the total-for-all-countries value on the same line. HS 2936 covers vitamins and provitamins ($1.37B total), HS 2106.90 covers food preparations not elsewhere specified ($6.04B total), and HS 3004 covers finished dosage medicaments ($97.5B total). These lines proxy different layers of the supplement supply chain; none is a perfect one-to-one for "supplements," which is why we read all three. Tariff and landed-cost figures are from Eightx benchmark analyses cited inline.

Frequently Asked Questions